Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) and Regeneron (REGN) are among the first seven companies selected for the FDA's PreCheck pilot program aimed at accelerating reviews of new pharmaceutical manufacturing facilities. The initiative allows regulators to review facilities during construction, potentially saving companies up to 14 months in review time. Lilly's facility in Lebanon, Indiana, and Regeneron's $2 billion site in Saratoga Springs, New York, are included in the program. This effort targets domestic drug production and involves companies producing biologic drugs and genetic medicines.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Tesla (TSLA) Market Moves Amid Dow Jones Futures Analysis
- Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
- Cathie Wood Sells $26.65M Robinhood (HOOD), Buys $46.18M Eli Lilly
- SpaceX (SPAC) Mega-IPO Drives Pharma Innovation in Orbit
- Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
